会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 10. 发明公开
    • PREDICTIVE OUTCOME ASSESSMENT FOR CHEMOTHERAPY WITH NEOADJUVANT BEVACIZUMAB
    • 精油ÜRÜUNG IE IE IE IE B B B B B B B B B B B B B B B B B B B
    • EP2925887A2
    • 2015-10-07
    • EP13826603.6
    • 2013-11-22
    • Koninklijke Philips N.V.
    • VARADAN, VinayKAMALAKARAN, SitharthanJANEVSKI, AngelBANERJEE, NilanjanaDIMITROVA, NevenkaHARRIS, Lyndsay
    • C12Q1/68
    • G06F19/24A61K39/3955A61K45/06C07K16/22C12Q1/6886C12Q2600/106C12Q2600/158G06F19/704
    • In a predictive outcome assessment test for predicting whether a patient undergoing a breast cancer treatment regimen will achieve pathological complete response (pCR), differential gene expression level information are generated for an input set of genes belonging to the TGF-&bgr; signaling pathway. The differential gene expression level information compares baseline gene expression level information from a baseline sample (70) of a breast tumor of a patient acquired before initiating (71) a breast cancer therapy regimen to the patient and response gene expression level information from a response sample (72) of the breast tumor acquired after initiating the breast cancer therapy regimen by administering a first dose of bevacizumab to the patient. A pCR prediction for the patient is computed based on the differential gene expression level information for the input set of genes belonging to the TGF-&bgr; signaling pathway. Related predictive outcome assessment test development methods are also disclosed.
    • 在用于预测经历乳腺癌治疗方案的患者是否将达到病理学完全应答(pCR)的预测性结果评估测试中,针对属于TGF-β的基因的输入集合产生差异基因表达水平信息。 信号通路。 差异基因表达水平信息比较了在开始(71)乳腺癌治疗方案与患者之前获得的患者的乳腺肿瘤的基线样品(70)的基线基因表达水平信息和来自响应样品的响应基因表达水平信息 (72)通过向患者施用第一剂贝伐珠单抗来启动乳腺癌治疗方案后获得的乳腺肿瘤。 基于属于TGF-β基因的输入基因组的差异基因表达水平信息计算患者的pCR预测值; 信号通路。 还公开了相关预测结果评估测试开发方法。